Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Geron, a company into developing biopharmaceuticals for the treatment of cancer and chronic degenerative diseases, including spinal cord injury, heart failure and diabetes, has reported revenues of $1m for the second quarter ended June 30, 2010 compared to $183,000 for the comparable period in 2009.
Subscribe to our email newsletter
Geron said that the revenues for the second quarter and year to date period of 2010 reflect funding from collaboration agreements and royalty and license fee revenues under various agreements.
Geron has posted a net loss of $17.0m for the second quarter 2010, or $0.18 per diluted share, compared to net loss of $19.9m, or $0.23 per diluted share, for the comparable period in 2009.
For the six months ended June 30, 2010, Geron has posted revenue of $1.9m compared to $627,000 for the year ago period.
For the six months ended June 30, 2010, Geron has posted a net loss of $33.7m, or $0.35 per diluted share, compared to $36.8m, or $0.43 per diluted share, for the year ago period.